Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Objectives Several studies have evaluated the economic evaluation of a group of
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …

Background: Anticoagulant therapy is used for stroke prevention and proved to be effective
and safe in the long term. The study aims to analyse the cost-effectiveness relationship of …

Background: In the clinical setting, the economic benefits of direct oral anticoagulants
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …

Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …

Purpose The genetic polymorphism was one of the major considerations for adjusting doses
of warfarin in Thai individuals. As a result, new oral anticoagulants (NOACs) were …

For more than 5 decades, the only available treatment for the prevention of atrial fibrillation
(AF)-related stroke were the vitamin K antagonists. Recently, novel oral anticoagulants …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …

Background: Low-and middle-income (LMICs) countries are facing with a high incidence of
cardiovascular diseases and limited resources for confronting these diseases. Atrial …